Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
In this trial, participants will be allocated to one of three cohorts. In cohort A, participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib and atezolizumab treatment during 28-day cycles. In cohort B, participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib prior to initiating atezolizumab treatment during Cycle 1. During subsequent 28-day cycles participants in cohort B will initiate both atezolizumab and cobimetinib on Day 1 of each cycle; participants in this cohort will undergo tumor biopsies before and during treatment. In cohort C, participants with advanced melanoma, who have not received previous treatment, will receive atezolizumab monotherapy during 21-day cycles.